Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases

American Journal of Pathology

Volumn 183, Issue 1, 2013, Pages 83-95

  Hohensee, Ina ^a   Lamszus, Katrin ^a   Riethdorf, Sabine ^a   Meyer Staeckling, Sönke ^a   Glatzel, Markus ^a   Matschke, Jakob ^a   Witzel, Isabell ^a   Westphal, Manfred ^a   Brandt, Burkhard ^a,b   Müller, Volkmar ^a   Pantel, Klaus ^a   Wikman, Harriet ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; DISTANT METASTASIS; EPIDERMAL GROWTH FACTOR 2 GENE; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER;

BONE NEOPLASMS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-1; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PTEN PHOSPHOHYDROLASE; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84879394366     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2013.03.023     Document Type: Article

References (44)

1. N.U. Lin, J.R. Bellon, and E.P. Winer CNS metastases in breast cancer J Clin Oncol 22 2004 3608 3617
2. J. Engel, R. Eckel, U. Aydemir, S. Aydemir, J. Kerr, A. Schlesinger-Raab, P. Dirschedl, and D. Holzel Determinants and prognoses of locoregional and distant progression in breast cancer Int J Radiat Oncol Biol Phys 55 2003 1186 1195
3. M.E. Shaffrey, M. Mut, A.L. Asher, S.H. Burri, A. Chahlavi, S.M. Chang, E. Farace, J.B. Fiveash, F.F. Lang, M.B. Lopes, J.M. Markert, D. Schiff, V. Siomin, S.B. Tatter, and M.A. Vogelbaum Brain metastases Curr Probl Surg 41 2004 665 741
4. P.D. Bos, X.H.-F. Zhang, C. Nadal, W. Shu, R.R. Gomis, D.X. Nguyen, A.J. Minn, M.J. Van de Vijver, W.L. Gerald, J.A. Foekens, and J. Massagué Genes that mediate breast cancer metastasis to the brain Nature 459 2009 1005 1009
5. K. Pantel, R.H. Brakenhoff, and B. Brandt Detection, clinical relevance and specific biological properties of disseminating tumour cells Nat Rev Cancer 8 2008 329 340
6. B. Gril, L. Evans, D. Palmieri, and P.S. Steeg Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies Eur J Cancer 46 2010 1204 1210
7. K. Takeuchi, and F. Ito Receptor tyrosine kinases and targeted cancer therapeutics Biol Pharm Bull 34 2011 1774 1780
8. S.A. Eccles The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology Int J Dev Biol 55 2011 685 696
9. T. Mukohara Role of HER2-targeted agents in adjuvant treatment for breast cancer Chemother Res Pract 2011 2011 730360
10. R. Govindan Summary of presentation from the targeted therapy in lung cancer meeting J Thorac Oncol 6 2011 S1757
11. D.E. Gerber Targeted therapies: a new generation of cancer treatments Am Fam Physician 77 2008 311 319
12. G. Metro, and A. Fabi New target therapies for brain metastases from breast cancer Curr Cancer Drug Targets 12 2012 210 217
13. A. Awada, I. Bozovic-Spasojevic, and L. Chow New therapies in HER2-positive breast cancer: a major step towards a cure of the disease? Cancer Treat Rev 38 2012 494 504
14. H. Wikman, K. Lamszus, N. Detels, L. Uslar, M. Wrage, C. Benner, I. Hohensee, B. Ylstra, K. Eylmann, M. Zapatka, G. Sauter, D. Kemming, M. Glatzel, V. Muller, M. Westphal, and K. Pantel Relevance of PTEN loss in brain metastasis formation of breast cancer patients Breast Cancer Res 14 2012 R49
15. M. Wrage, S. Ruosaari, P.P. Eijk, J.T. Kaifi, J. Hollmén, E.F. Yekebas, J.R. Izbicki, R.H. Brakenhoff, T. Streichert, S. Riethdorf, M. Glatzel, B. Ylstra, K. Pantel, and H. Wikman Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion Clin Cancer Res 15 2009 1566 1574
16. J. Hannemann, S. Meyer-Staeckling, D. Kemming, I. Alpers, S.A. Joosse, H. Pospisil, S. Kurtz, J. Görndt, K. Püschel, S. Riethdorf, K. Pantel, and B. Brandt Quantitative high-resolution genomic analysis of single cancer cells PLoS One 6 2011 e26362
17. C. Kersting, N. Tidow, H. Schmidt, C. Liedtke, J. Neumann, W. Boecker, P.J. Van Diest, B. Brandt, and H. Buerger Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma Lab Invest 84 2004 582 587
18. I.K. Mellinghoff, M.Y. Wang, I. Vivanco, D.A. Haas-Kogan, S. Zhu, E.Q. Dia, K.V. Lu, K. Yoshimoto, J.H. Huang, D.J. Chute, B.L. Riggs, S. Horvath, L.M. Liau, W.K. Cavenee, P.N. Rao, R. Beroukhim, T.C. Peck, J.C. Lee, W.R. Sellers, D. Stokoe, M. Prados, T.F. Cloughesy, C.L. Sawyers, and P.S. Mischel Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors N Engl J Med 353 2005 2012 2024
19. S.A. Danielsen, G.E. Lind, M. Bjørnslett, G.I. Meling, T.O. Rognum, S. Heim, and R.A. Lothe Novel mutations of the suppressor gene PTEN in colorectal carcinomas stratified by microsatellite instability-and TP53 mutation-status Hum Mutat 29 2008 E252 E262
20. A.C. Wolff, M.E.H. Hammond, J.N. Schwartz, K.L. Hagerty, D.C. Allred, R.J. Cote, M. Dowsett, P.L. Fitzgibbons, W.M. Hanna, A. Langer, L.M. McShane, S. Paik, M.D. Pegram, E.A. Perez, M.F. Press, A. Rhodes, C. Sturgeon, S.E. Taube, R. Tubbs, G.H. Vance, M. Van de Vijver, T.M. Wheeler, and D.F. Hayes American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 2007 118 145
21. S. Riethdorf, B. Hoegel, B. John, G. Ott, P. Fritz, S. Thon, T. Loening, and K. Pantel Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients J Cancer Res Clin Oncol 137 2011 261 269
22. J. Boström, J.M. Cobbers, M. Wolter, G. Tabatabai, R.G. Weber, P. Lichter, V.P. Collins, and G. Reifenberger Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q Cancer Res 58 1998 29 33
23. K. Omholt, D. Kröckel, U. Ringborg, and J. Hansson Mutations of PIK3CA are rare in cutaneous melanoma Melanoma Res 16 2006 197 200
24. A.F. Eichler, E. Chung, D.P. Kodack, J.S. Loeffler, D. Fukumura, and R.K. Jain The biology of brain metastases-translation to new therapies Nat Rev Clin Oncol 8 2011 344 356
25. T. Mukohara Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer Cancer Sci 102 2011 1 8
26. J. Gaedcke, F. Traub, S. Milde, L. Wilkens, A. Stan, H. Ostertag, M. Christgen, R. Von Wasielewski, and H.H. Kreipe Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer Mod Pathol 20 2007 864 870
27. B. Adamo, A.M. Deal, E. Burrows, J. Geradts, E. Hamilton, K.L. Blackwell, C. Livasy, K. Fritchie, A. Prat, J.C. Harrell, M.G. Ewend, L.A. Carey, C.R. Miller, and C.K. Anders Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases Breast Cancer Res 13 2011 R125
28. N.L. Grupka, K.C. Lear-Kaul, B.K. Kleinschmidt-DeMasters, and M. Singh Epidermal growth factor receptor status in breast cancer metastases to the central nervous system. Comparison with HER-2/neu status Arch Pathol Lab Med 128 2004 974 979
29. Y. Nieto, F. Nawaz, R.B. Jones, E.J. Shpall, and S. Nawaz Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer J Clin Oncol 25 2007 4405 4413
30. T.M. Brand, M. Iida, and D.L. Wheeler Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab Cancer Biol Ther 11 2011 777 792
31. A.M. Gonzalez-Angulo, J. Ferrer-Lozano, K. Stemke-Hale, A. Sahin, S. Liu, J.A. Barrera, O. Burgues, A.M. Lluch, H. Chen, G.N. Hortobagyi, G.B. Mills, and F. Meric-Bernstam PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer Mol Cancer Ther 10 2011 1093 1101
32. E. López-Knowles, S.A. O'Toole, C.M. McNeil, E.K. Millar, M.R. Qiu, P. Crea, R.J. Daly, E.A. Musgrove, and R.L. Sutherland PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality Int J Cancer 126 2010 1121 1131
33. S. Boyault, Y. Drouet, C. Navarro, T. Bachelot, C. Lasset, I. Treilleux, E. Tabone, A. Puisieux, and Q. Wang Mutational characterization of individual breast tumors: tP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes Breast Cancer Res Treat 132 2012 29 39
34. G. Pérez-Tenorio, L. Alkhori, B. Olsson, M.A. Waltersson, B. Nordenskjöld, L.E. Rutqvist, L. Skoog, and O. Stål PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer Clin Cancer Res 13 2007 3577 3584
35. C.-H. Huang, D. Mandelker, O. Schmidt-Kittler, Y. Samuels, V.E. Velculescu, K.W. Kinzler, B. Vogelstein, S.B. Gabelli, and L.M. Amzel The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations Science 318 2007 1744 1748
36. J.D. Jensen, A. Knoop, A.V. Laenkholm, M. Grauslund, M.B. Jensen, E. Santoni-Rugiu, M. Andersson, and M. Ewertz PIK3CA mutations. PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab Ann Oncol 23 2012 2034 2042
37. L.H. Saal, P. Johansson, K. Holm, S.K. Gruvberger-Saal, Q.-B. She, M. Maurer, S. Koujak, A.A. Ferrando, P. Malmström, L. Memeo, J. Isola, P.-O. Bendahl, N. Rosen, H. Hibshoosh, M. Ringnér, A. Borg, and R. Parsons Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity Proc Natl Acad Sci U S A 104 2007 7564 7569
38. K. Stemke-Hale, A.M. Gonzalez-Angulo, A. Lluch, R.M. Neve, W.-L. Kuo, M. Davies, M. Carey, Z. Hu, Y. Guan, A. Sahin, W.F. Symmans, L. Pusztai, L.K. Nolden, H. Horlings, K. Berns, M.-C. Hung, M.J. Van de Vijver, V. Valero, J.W. Gray, R. Bernards, G.B. Mills, and B.T. Hennessy An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer Cancer Res 68 2008 6084 6091
39. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
40. I. Fuchs, M. Loebbecke, and H. Buhler HER2 in brain metastases: issues of concordance, survival, and treatment J Clin Oncol 20 2002 4130 4133
41. R. Nishimura, T. Osako, Y. Okumura, R. Tashima, Y. Toyozumi, and N. Arima Changes in the ER. PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis World J Surg Oncol 9 2011 131
42. C. Alix-Panabières, H. Schwarzenbach, and K. Pantel Circulating tumor cells and circulating tumor DNA Annu Rev Med 63 2012 199 215
43. B. Gumuskaya, M. Alper, S. Hucumenoglu, K. Altundag, A. Uner, and G. Guler EGFR expression and gene copy number in triple-negative breast carcinoma Cancer Genet Cytogenet 203 2010 222 229
44. C. Gasch, T. Bauernhofer, M. Pichler, S. Langer-Freitag, M. Reeh, A.M. Seifert, O. Mauermann, J.R. Izbicki, K. Pantel, and S. Riethdorf Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer Clin Chem 59 2013 252 260